Donna Cochener - Mar 14, 2022 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NLTX)

Role
General Counsel, SVP Legal
Signature
/s/ Sean Smith, as Attorney-in-Fact for Donna Cochener
Stock symbol
NLTX
Transactions as of
Mar 14, 2022
Transactions value $
$0
Form type
4
Date filed
3/15/2022, 06:05 PM
Next filing
Aug 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NLTX Stock Option (Right to Buy) Award $0 +400K $0.00 400K Mar 14, 2022 Common Stock 400K $1.81 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/4 of the total shares on March 14, 2023, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.